1 Min Read
Oct 9 (Reuters) - Endo International Plc said it would buy Auxilium Pharmaceuticals Inc in a deal valued at $2.6 billion, including the repayment and assumption of debt.
Endo's offer of $33.25 per share represents a premium of about 12 percent to Auxilium's Wednesday close and is higher than Endo's previous offer of $28.10.
The deal has an equity value of $1.67 billion, according to a Reuters calculation.
As part of the deal, Auxilium terminated its proposed merger agreement with Canadian eye-drug maker QLT Inc. (Reporting by Ankur Banerjee in Bangalore; Editing by Savio D'Souza)